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Abstract
In clinic, the luteinizing (LH) and follicle-stimulating (FSH) hormones and 
human chorionic gonadotropin (hCG) are used to treat reproductive dysfunctions 
and in assisted reproductive technology. They are the αβ-heterodimeric complexes 
and specifically bind to ectodomain of G protein-coupled LH and FSH receptors. 
This leads to activation of many signaling cascades; some of which are responsible 
for steroidogenesis, folliculogenesis, and spermatogenesis, while the others, such 
as β-arrestin pathways, trigger the downregulation of gonadotropin receptors. A 
low selectivity of the intracellular signaling of gonadotropins and a large number of 
their isoforms are the main causes of undesirable effects of gonadotropins, limiting 
their clinical applications. Unlike gonadotropins, the low-molecular-weight (LMW) 
ligands interact with an allosteric site located in the transmembrane domain of 
the LH and FSH receptors and selectively activate the certain signaling pathway, 
preventing a number of side effects of gonadotropins. The LMW ligands are charac-
terized by activity of the full and inverse agonists and neutral antagonists, as well as 
the positive and negative modulators, and they have the in vivo activity, including 
when administered orally. This review focuses on the advances in the development 
of LMW allosteric ligands of the LH and FSH receptors and the prospects for their 
use in reproductive medicine.
Keywords: sex steroid hormone, steroidogenesis, low-molecular-weight agonist, 
luteinizing hormone, follicle-stimulating hormone, receptor of luteinizing hormone
1. Introduction
The most important areas of clinical applications of the gonadotropins, such 
as the luteinizing (LH) and follicle-stimulating (FSH) hormones and human 
chorionic gonadotropin (hCG), are (i) the stimulation of the steroidogenesis, 
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folliculogenesis, and spermatogenesis in patients with the dysfunctions in the 
hypothalamo-pituitary-gonadal axis, (ii) the induction of ovulation in the assisted 
reproductive technologies, and (iii) the treatment of sex hormone-dependent 
tumors [1–4]. The gonadotropins with LH activity are isolated from the urine of 
pregnant women (the urinary forms of hCG) or produced in the specialized cel-
lular cultures (the recombinant forms of LH and hCG), while FSH is isolated from 
the urine of postmenopausal women (the urinary forms of FSH) or produced by 
genetic engineering approaches (the recombinant forms of FSH) [1, 5, 6]. Despite 
the fact that these forms of gonadotropins are widely used in the clinic, they have 
the significant side effects. In the case of urinary forms of hCG and FSH, the main 
disadvantages are the presence of biologically active impurities in the gonadotro-
pin preparations and a low degree of its standardization [2, 7]. The placental hCG 
differs significantly in both the structure and functions from the LH and sulfated 
hCG which are secreted by the pituitary gonadotrophs and circulate in the blood 
of adult men and women [2, 8]. Furthermore, the placental hCG is produced only 
during pregnancy and regulates the growth and development of the embryo [9]. 
The urinary FSH contains mainly highly glycosylated forms of this gonadotro-
pin with the reduced activity, which associated with the impaired reproductive 
functions and infertility at the postmenopausal period [10]. At the same time, 
the recombinant forms of gonadotropins differ from their natural forms in the 
posttranslational modifications, primarily in the number, structure, and charge 
of N-glycans, which significantly changes their specific biological activity and 
pharmacological profile. All this not only significantly limits the use of natural 
and recombinant forms of gonadotropins in the treatment of androgen deficiency, 
hypogonadotropic hypogonadism, and amenorrhea but also reduces their effec-
tiveness in the controlled induction of ovulation and in other assisted reproductive 
technologies.
Thus, one of the urgent tasks of reproductive medicine is to minimize the 
side effects of gonadotropins and to increase their effectiveness and specificity. 
An alternative approach is the development of a new generation of the selective 
regulators of the LH and FSH receptors, the most suitable among which are the 
low-molecular-weight (LMW) allosteric ligands of these receptors.
2.  The LH and FSH receptors and their binding with the gonadotropins 
and the low-molecular-weight allosteric ligands
The LH and FSH receptors belong to the δ group of the rhodopsin family of the 
G protein-coupled receptors (GPCR) and contain seven membrane-penetrating 
hydrophobic regions that form the heptahelical transmembrane channel [11–16]. 
Unlike most GPCRs with a short extracellular N-terminal region, the gonadotro-
pin receptors have a large-size extracellular domain (an ectodomain) containing 
the leucine-rich repeats (LRRs). The LRRs are involved in the formation of an 
orthosteric site responsible for a high-affinity binding of the receptors with 
gonadotropins. The gonadotropins are the αβ-heterodimeric complexes, in which 
the α-subunit encoded by a single gene is identical in all gonadotropins, while the 
β-subunits are encoded by separate genes and differ in the primary structure and 
modifications. The αβ-heterodimeric complexes of gonadotropins are stabilized by 
the cystine knots that ensure a close contact between the central regions of the α- 
and β-subunits [12, 16]. The β-subunit is responsible for the specificity of gonado-
tropins binding with the LH and FSH receptors, while the α-subunit provides the 
physical contacts between the ligand-bound ectodomain and the transmembrane 
domain. The binding of gonadotropin with an ectodomain induces conformational 
3The Low-Molecular-Weight Ligands of the Gonadotropin Receptors as the New Generation…
DOI: http://dx.doi.org/10.5772/intechopen.88498
changes in both the transmembrane channel and the intracellular regions of the LH 
and FSH receptors, which are responsible for their functional coupling with the het-
erotrimeric G proteins (Gs, Gq/11, and Gi/o) and β-arrestins, resulting in the activa-
tion of a large number of the intracellular signaling cascades and the transcriptional 
factors [15–18] (Figure 1).
By activating the Gs proteins, the gonadotropins stimulate the enzyme 
adenylyl cyclase (AC), which leads to an increase in the intracellular cAMP lev-
els and the activation of protein kinase A (PKA) and exchange protein directly 
activated by cyclic AMP (Epac). The stimulation of PKA leads to activation of 
the transcriptional factor cAMP-response element binding protein (CREB), 
which controls the expression of a large number of PKA-dependent genes, while 
the activation of Epac induces the stimulation of phosphatidylinositol-3-kinase, 
mitogen-activated protein kinases (MAPKs), and the other effector enzymes. 
The gonadotropin-induced activation of the cAMP-dependent pathways is 
the key mechanism for triggering the steroidogenesis, spermatogenesis, and 
folliculogenesis (Figure 1). By activating Gq/11 proteins, the gonadotropins 
stimulate the phosphoinositide-specific phospholipase Cβ (PLCβ), which 
catalyzes the formation of inositol-3,4,5-triphosphate and diacylglycerol, the 
important second messengers. This induces the activation of calcium-dependent 
signaling and different isoforms of protein kinase C [15–19]. A specific inter-
action between the β-arrestins and the GPCR kinases-phosphorylated sites 
located within the intracellular loops of the LH and FSH receptors induces G 
Figure 1. 
The signaling pathways of the gonadotropins with LH-like activity and the Gs protein-selective LMW agonists. 
(A) The gonadotropins, LH and hCG, specifically bind to an ectodomain of LH receptor, which triggers the 
conformational changes in its serpentine domain and provokes the interaction of the intracellular regions of 
the receptor with the G proteins (Gs and Gq/11) and β-arrestins. The result of this is activation of the cAMP-
dependent and phosphoinositide signaling pathways and the cascade of mitogen-activated protein kinases, 
which control the steroidogenesis, growth, differentiation, and apoptosis in the cells of reproductive tissues. 
A specific interaction of gonadotropin-activated LH receptor with β-arrestins induces the endocytosis of LH 
receptor, its degradation, or recycling. (B) The Gs-selective LMW agonists bind to the allosteric site located 
within the transmembrane channel of LH receptor and activate the Gs protein, triggering cAMP-signaling 
pathways. At the same time, these agonists do not have a significant effect on other signaling pathways. 
Abbreviations: AC, adenylyl cyclase; hCG, human chorionic gonadotropin; LH, luteinizing hormone; MAPK, 
mitogen-activated protein kinase; PKA, protein kinase A; PLC, phosphoinositide-specific phospholipase Cβ.
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protein-independent stimulation of the MAPK cascade and is involved in the 
internalization, endocytosis, and recyclization of the gonadotropin receptor 
complexes [18–22]. The Ca2+- and β-arrestin-dependent pathways, as well as 
the AC signaling system, are involved in the regulation of the synthesis and 
secretion of sex steroid hormones and also control the growth, differentiation, 
and survival of the testicular and ovarian cells (Figure 1). About two-thirds of 
gonadotropin-dependent genes are regulated through cAMP-dependent mecha-
nisms, while the expression of another third of the genes is regulated through 
cAMP-independent mechanisms [23].
The choice of the intracellular signaling pathway depends on the stability and 
the ratio of active conformations of the LH and FSH receptors, which, in turn, 
is determined by (i) the type of gonadotropin and the structural features of its 
α- and β-subunits (the N-glycosylation, site-specific proteolysis, etc.), (ii) the 
structural features of the LH and FSH receptors (the posttranslational modifica-
tions, mutations, polymorphisms, etc.), and their ability to form the dimeric and 
oligomeric complexes, as well as (iii) the functional activity of the downstream 
regulatory and accessory proteins (the G proteins, β-arrestins, etc.) [6, 19, 24, 25]. 
A specific binding of gonadotropin to ectodomain generates a large set of the active 
conformations of receptor, which triggers some intracellular pathways at once 
and, as a result, induces multiple cell responses. For example, the placental hCG 
with a high efficiency stimulates the cAMP-dependent signaling pathways, being a 
powerful activator of the steroidogenesis, but its stimulating effect on the Gq/11-
mediated signaling is realized to a much lesser extent. Moreover, the recombinant 
LH with a high efficiency stimulates the PLCβ- and β-arrestin-dependent signaling 
pathways, but weakly, in comparison with hCG, stimulates the cAMP-signaling 
and steroidogenesis [18].
Unlike gonadotropins, the ligands of the allosteric site that is located within 
the transmembrane channel of the LH and FSH receptors more selectively regu-
late the intracellular signaling cascades. This is due to the fact that, by binding to 
the allosteric site, they stabilize, as a rule, only one conformation of the gonado-
tropin receptor, either active or inactive. In the first case, they function as the 
full allosteric agonists or as the positive allosteric modulators (PAMs), enhancing 
the stimulating effects of gonadotropins, or as the ago-PAM, combining the 
effects of allosteric agonists and “pure” PAMs. In the second case, they function 
as the allosteric antagonists or as the negative allosteric modulators (NAMs) that 
prevent the activation of the LH and FSH receptors by gonadotropins [26]. Since 
the binding sites for the gonadotropins and the LMW allosteric ligands do not 
overlap, there is no competition between them. Due to this, in the case of co-
administration of the gonadotropin and LMW agonist, their stimulating effects 
can be additive and even synergistic. Below we consider the most effective LMW 
allosteric ligands of the LH and FSH receptors, which were developed by us and 
the other authors.
3.  Thienopyrimidine-based low-molecular-weight agonists of the 
luteinizing hormone receptor
Screening of a large number of organic compounds allowed to identify the 
1,3,5-substituted pyrazole and terphenyl derivatives, which have the activity 
of the full and inverse allosteric agonists of LH receptor [27–30]. It was shown 
that a derivative of terphenyl, the compound LUF5771, inhibited the gonado-
tropin- and LMW agonist-induced stimulation of LH receptor, indicating that 
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the LUF5771 belongs to the inverse agonists. This compound can be used as a 
prototype to develop the contraceptives and the anticancer drugs for treatment 
of hormone-dependent tumors [29]. The 1,3,5-substituted pyrazole derivative, 
8-(1-(4-(tert-butyl)phenyl)-3-(pyridin-3-yl)-1H-pyrazol-5-yl)-2-(4-hydroxy-
benzyl)-4-oxooctanamide (1) (Figure 2), had activity of the full agonist of LH 
receptor [27]. It stimulated the AC activity (EC50, 20 nM) and increased the syn-
thesis and secretion of testosterone by the Leydig cells (ED50, 1.31 μM), and when 
Figure 2. 
The pyrazole- and thienopyrimidine-based low-molecular-weight agonists of LH receptor. (1) 8-(1-(4-(tert-
butyl)phenyl)-3-(pyridin-3-yl)-1H-pyrazol-5-yl)-2-(4-hydroxybenzyl)-4-oxooctanamide [27]; (2) 
Compound Org 41,841, N-tert-butyl-5-amino-4-(3-methoxyphenyl)-2-(methylthio)thieno[2,3-d]
pyrimidine-6-carboxamide [31]; (3) Compound Org 43,553, 5-amino-N-(tert-butyl)-2-(methylthio)-4-(3-(2-
morpholinoacetamido)phenyl)thieno[2,3-d]pyrimidine-6-carboxamide [31]; (4) Compound TP01, 5-amino-
N-(tert-butyl)-4-(3-(isonicotinamido)phenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide [32]; 
(5) Compound TP03, 5-amino-N-tert-butyl-2-(methylsulfanyl)-4-(3-(nicotinamido)phenyl)thieno[2,3-d]
pyrimidine-6-carboxamide [33]; (6) Compound TP23, 5-amino-N- (tert-butyl)-4-(3-(2-chloronicotinamido)
phenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide [34].
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administered intraperitoneally to male rats, this compound stimulated the testos-
terone production in them [27]. However, the greatest success was achieved in the 
development of the thienopyrimidine-based agonists of LH receptor.
In 2002, as a result of screening of a large number of the organic compounds, 
the Dutch scientists from the Organon Company discovered the first compounds 
with activity of LH receptor agonists belonging to the thienopyrimidines [31]. 
The most effective among them were the compound Org 41,841 and its analogue 
Org 43,553 (Figure 2). Later, the pharmacological characteristics of Org 43,553 
and the mechanisms of its action were studied, and this compound was consid-
ered as the “gold” standard for the allosteric agonists of LH receptor [35–39]. 
Based on Org 43,553 structure, we have developed and studied the series of 
the thienopyrimidine derivatives that with a high efficiency stimulated the AC 
activity and steroidogenesis in the Leydig cells in both the in vitro and in vivo 
conditions [33–35, 40–42]. The most active among these derivatives were the 
compounds TP01, TP03, and TP23 (Figure 2). The study of thienopyrimidine-
based LMW agonists of LH receptor allowed identifying the mechanisms of their 
action and the pharmacological profile, which can be an advantage when using 
these compounds in the clinic.
Using the Org 41,841 and Org 43,553, the allosteric sites in the transmembrane 
channels of gonadotropins receptors and related to them thyroid-stimulating 
hormone (TSH) receptor were carried out. This allowed to detect the structural 
features of the active and inactive conformations of the serpentine domain of 
gonadotropins receptors, to identify the amino acid residues involved in the forma-
tion of their allosteric sites, and to decipher the mechanisms of signal transduction 
through these receptors [43, 44]. Based on the site-directed mutagenesis, the amino 
acid residues in the second extracellular loop (ECL2) and within the fifth and sixth 
transmembrane regions (TM5 and TM6) of TSH receptor, which form its allosteric 
site, were replaced with the corresponding amino acids of LH receptor, which made 
the allosteric site of TSH receptor similar to that in LH receptor. It was found that 
a single substitution, Leu570Phe, in the ECL2 of TSH receptor resulted in the Org 
41,841 binding with a mutant receptor with the EC50 of 800 nM, while the double 
substitutions, the Leu570Phe/Phe585Thr and Leu570Phe/Tyr643Phe, led to the Org 
41,841 binding with the EC50 of 1000 nM. These data indicate an important role 
of the residues Lуг570Phe, Phe585Thr, and Tyr643Phe in the formation of the allo-
steric site in LH receptor [43]. The simultaneous replacement of nine amino acids 
(Ile560Val and Leu570Phe in the ECL2; Prp577Thr, Ala579Ser, Leu580Gln, Ala581Val, and 
Phe585Thr in the TM5; and Tyr643Phe and Ile648Ala in the TM6) that form the alloste-
ric site of TSH receptor with the corresponding amino acids of LH receptor induced 
a high-affinity binding of Org 41,841 with mutant TSH receptor, similar to that of 
LH receptor. In the cells with expressed mutant TSH receptor, the AC stimulating 
effects induced by the Org 41,841 and TSH were similar [43]. It was also shown that 
the negatively charged Glu506 located in the TM3 of the LH and TSH receptors has a 
key role in specific interaction with Org 41,841, since the substitution of Glu506Ala 
inhibits both the Org 41,841 binding to mutant LH receptor and the AC stimulating 
effect of Org 41,841 [43, 44].
The allosteric LMW agonists stabilize any one active conformation and, thereby, 
selectively stimulate preferably one intracellular cascade. It was shown that the Org 
43,553 (1–10 μM) stimulated the activity of PLCβ by 33–37%, which is less than 
5% of the corresponding effect of LH [36]. Moreover, the Org 43,553 effectively 
stimulated the activity of AC and cAMP-dependent transcription factors at lower 
concentrations. Based on these data, a conclusion was made on the selectivity of 
stimulating influence of Org 43,553 on the AC signaling system, which is realized 
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through the Gs proteins and on the inefficiency of this compound in regard to the 
Gq/11 proteins and PLCβ-dependent signaling [36].
Using the bacterial toxin-induced ADP ribosylation and the peptide strategy, 
we showed the selectivity of the thienopyrimidine derivative TP03, as a stimulator 
of the AC signaling system in the rat testicular and ovarian membranes [45]. In 
the membranes treated with cholera toxin that hyperactivates the Gs proteins and 
prevents the signal transduction through them, the stimulating effects of TP03 
on the AC activity and the GTP binding were suppressed. At the same time, the 
treatment of the plasma membranes with pertussis toxin, which inhibits the Gi 
proteins, and their incubation with the peptide 349–359 of Gαq/11-subunit, which 
leads to uncoupling of the LH receptor and Gq/11 proteins, did not affect the regula-
tory effects of TP03. Only at high concentrations (10–100 μM), the TP03 effect 
on the GTP binding of Gq/11 proteins was detected but to a small extent. Under the 
same conditions, the regulatory effects of hCG were not specific for different types 
of G proteins [45]. It should be noted that the thienopyrimidine derivatives and 
the other allosteric ligands of LH receptor, which did not affect the AC activity and 
the steroidogenesis, are usually excluded from further research. However, they 
can activate Gs-independent signaling cascades, including the Gq/11 proteins and 
β-arrestins. As a consequence, these compounds may be of interest for studying the 
molecular mechanisms of the allosteric regulation of LH receptors and can be used 
in medicine.
The selectivity of signal transduction may have an important role in maintain-
ing the tissue sensitivity to both the gonadotropins and LMW agonists, which was 
demonstrated by us in the case of TP03 [42]. Despite the fact that hCG and TP03 
increased the testosterone levels during the 7-day treatment of male rats, a dynam-
ics of this effect differed significantly. In long-term hCG treatment, an increase in 
the plasma testosterone concentration was the maximum on the first day, and then 
it decreased. At the same time, the steroidogenic effect of TP03, on the contrary, 
gradually increased, reaching a maximum on the seventh day of treatment. On the 
first day of treatment, TP03-induced increase in the testosterone concentration was 
4 times lower than that in the case of hCG, while at the end of the experiment, the 
steroidogenic effects of hCG and TP03 were comparable [42]. One of the causes 
for this may be the specific changes in the LH receptor sensitivity to gonadotropins 
and thienopyrimidines, as well as the different mechanisms of their action on 
steroidogenesis.
A long-term administration of hCG to male rats leads to a significant decrease 
in the testicular expression of the Lhr gene encoding LH receptor, while a long-
term administration of TP03 induces an increase in the Lhr gene expression, 
which is one of the factors maintaining the sensitivity of the Leydig cells to 
gonadotropins [42]. It should be noted that the gonadotropin resistance of the 
reproductive tissues is one of the urgent problems of the LH and hCG applica-
tions to treat the reproductive dysfunctions and in the assisted reproductive 
technologies [17, 46]. In our experiments, both the hCG and TP03 increased the 
expression of the Star gene, which encodes the steroidogenic acute regulatory 
protein (StAR) responsible for cholesterol transport into mitochondria, the 
rate-limiting stage of steroidogenesis, and gonadotropin in this regard was more 
active [42]. It was shown that the more the Lhr gene expression and the steroido-
genic effect of the drug on testosterone production were decreased, the more the 
Star gene expression was increased. This may indicate a compensatory mecha-
nism for increasing the Star gene expression in the conditions of the impaired 
gonadotropin signaling and the reduced PKA-induced stimulation of the StAR 
protein in the Leydig cells.
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In the case of a long-term treatment of male rats with hCG, the intratesticular 
expression of the Cyp11a1 gene encoding the C27 cholesterol side-chain cleavage 
cytochrome P450 (cytochrome Р450scc) that converts cholesterol to pregnenolone 
was significantly increased, and on the seventh day, the expression of the Hsd3b 
gene encoding the 3β-hydroxysteroid dehydrogenase/Δ5–4 isomerase (3β-HSD) 
that converts pregnenolone to progesterone was also increased. When the TP03 was 
used, there were no significant changes in the expression of the Cyp11a1 and Hsd3b 
genes, which indicates a stable functioning of the steroidogenesis system in the 
conditions of a long-term treatment of animals with LMW agonist [42].
Along with the selectivity of the intracellular signaling induced by the thieno-
pyrimidine derivatives, which identifies them as the selective bias agonists of LH 
receptor, their pharmacokinetic characteristics also contribute to the stability of 
the steroidogenic effect of these LMW agonists. When administered to rats, the 
Org 43,553 shows a half-life time of 3.4 hours, while the half-life time for hCG is 
6.6 hours, indicating the more rapid degradation and excretion of LMW agonist 
than gonadotropin [37]. Reducing the half-life time for thienopyrimidines is of 
great practical importance, since it contributes to maintaining the tissue sensitivity 
to endogenous gonadotropins and, in addition, reduces the risk of ovarian hyper-
stimulation syndrome, a severe complication of gonadotropin-induced ovarian 
stimulation in the assisted reproductive technologies. Unlike gonadotropins, both 
the single and long-term treatments of female rats with Org 43,553 did not cause 
an increase in the ovarian diameter and the vascular permeability in the ovary and 
did not provoke the development of ovarian hyperstimulation syndrome [38]. 
Also, there were no signs of the ovarian hyperstimulation syndrome in women who 
received Org 43,553 orally at the doses from 25 to 900 mg. In 83% of women, the 
administration of Org 43,553 at a single dose of 300 mg caused the ovulation and 
the production of high-quality oocytes [47].
Since the orthostatic and allosteric sites in LH receptor do not overlap, the LMW 
allosteric agonists do not inhibit the specific LH and hCG binding [27, 35, 36]. 
Moreover, the AC stimulating effects of the LMW agonists and gonadotropins are 
additive, at least in a range of their concentrations lower than the EC50 values [33, 
35, 36, 41]. As shown by us, the steroidogenic effect of hCG in male rats pretreated 
with the TP03 was enhanced significantly, and this potentiating effect of TP03 was 
most pronounced at the low doses of hCG (Shpakov, Bakhtyukov and Derkach, 
unpublished data). This effect of thienopyrimidines can be due to their chaperone-
like properties (Figure 3). It was shown that the Org 42,599, the trifluoroacetate salt 
of Org 43,553, restored the activity of the mutant LH receptors with the Ala593Pro 
and Ser616Tyr replacements [48]. The incubation of the cells expressing these recep-
tors with Org 42,599 led to an increase in the expression of the mutant receptors, 
the number of the receptors with the appropriate folding, and membrane topology 
and the receptor density on the cell surface. The chaperone-like properties of Org 
42,599 are due to its ability to penetrate the plasma membrane and specifically bind 
to an allosteric site of intracellularly located LH receptors, which promotes their 
efficient translocation into the plasma membrane of the Leydig cells [48]. It should 
be emphasized that the LH receptors with the Ala593Pro and Ser616Tyr mutations in 
the transmembrane regions are not capable of translocation into the cell surface and 
cannot be activated by gonadotropins. These mutations were found in patients with 
hypoplasia of the Leydig cells [49–52].
The allosteric sites of closely related GPCRs are known to be characterized 
by the variability of the primary structure and the three-dimensional organiza-
tion, which in most cases makes the allosteric regulators more specific than the 
orthosteric regulators [26, 53]. In the case of the receptors of pituitary glycoprotein 
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hormones, the specificity of LMW agonists to their allosteric site is not so high that 
it can be assumed to be due to the inverted position of the orthosteric and allosteric 
sites in these receptors as compared to other GPCRs belonging to class A [26]. At the 
same time, we and other authors showed that the Org 43,553, TP01, TP03, and TP23 
have a very weak effect on the activity of the FSH and TSH receptors [36, 54]. When 
administered to male rats, the TP01, TP03, and TP23 did not affect the basal and 
thyroliberin-stimulated levels of thyroid hormones [54].
4.  The low-molecular-weight ligands of the follicle-stimulating hormone 
receptor
The first LMW allosteric agonist of FSH receptor, a piperidine carboxamide, 
was developed in 2001. It stimulated the AC activity in the CHO cells expressing 
the FSH receptor (EC50, 3.9 nM) but was not active in the in vivo conditions [55]. A 
search for new LMW ligands of FSH receptor revealed a large number of the com-
pounds with different pharmacological activity [39, 56–58]. They belong to differ-
ent classes of the organic compounds, such as the thiazolidines [59–62], substituted 
γ-lactams [63], diketopiperazines [64, 65], N-alkylated sulfonyl piperazines [66], 
tetrahydroquinolines [67], hexahydroquinolines [68, 69], thienopyrimidines [70], 
and benzamides [69]. Among the developed LMW ligands, the thiazolidines, hexa- 
and tetrahydroquinolines, and benzamides with activity of the full and inverse 
agonists and the neutral antagonists of FSH receptor are of the greatest interest.
Figure 3. 
The chaperone-like properties of the LMW allosteric agonists. (A) The LMW agonist, being a hydrophobic 
substance, penetrates the plasma membrane, interacts with normal LH receptors located in the intracellular 
vesicles, and ensures their effective translocation into the plasma membrane of Leydig cells (1). This effect can 
be realized in the case of the mutant LH receptors that are not capable of normal posttranslational processing 
and translocation into the membrane (2). As a result, the treatment with the LMW agonists leads to the 
preservation and even to an increase in the sensitivity of LH-competent cells to LH and hCG. B. In the absence 
of agonists, the mutant LH receptors are not able to translocate into the membrane (3), while the normal 
forms of the receptor are retained within the cell for a longer time (4). All this leads to a weakened response to 
gonadotropins with LH activity.
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In 2004, compound 2 belonging to the thiazolidines was developed (Figure 4). It 
suppressed FSH-induced stimulating effects and, by its pharmacological profile, was 
classified as an inverse agonist [59]. Based on its structure, the thiazolidine derivatives 
with the activity of the full agonists were developed [60, 61, 63], including highly 
active compound 5 (Figure 4). This compound stimulated the cAMP-dependent cas-
cades and the steroidogenesis in the cell cultures and in the in vivo conditions induced 
the development of preovulatory follicles and stimulated the ovulation in immature 
female rats [61, 72]. Compound 5 was able to enhance the stimulating effects of 
low-dose FSH, acting as the PAM for FSH receptor. Another thiazolidine derivative, 
compound 3 (Figure 4), at the low concentrations activated the Gs proteins and 
stimulated the cAMP-dependent cascades in the cells expressing the FSH receptor, 
functioning as a full agonist. At the same, at the high concentrations, compound 
3 inhibited FSH-induced activation of Gs proteins and stimulated the Gi proteins, 
reducing the activity of AC and cAMP-dependent transcription factors, functioning 
as the NAM [62, 73].
Figure 4. 
The low-molecular-weight allosteric agonists and antagonists of the FSH receptor. (1) Compound 2, 
4-(5-(2-((2-(1H-indol-3-yl)ethyl)amino)-2-oxoethyl)-2-(4-(benzyloxy)phenyl)-4-oxothiazolidin-
3-yl)-2-chlorobenzamide [59]; (2) Compound 5, 3-(2S,5R)-5-(2-((3-ethoxy-4-methoxyphenethyl)
amino)-2-oxoethyl)-4-oxo-2-(4-(phenylethynyl)phenyl)thiazolidin-3-yl)benzamide [61]; (3) Compound 3, 
3-(2S,5R)-5-(2-((2-(1H-indol-3-yl)ethyl)amino)-2-oxoethyl)-4-oxo-2-(5-(phenylethynyl)thiophen-2-yl)
thiazolidin-3-yl)benzamide [62]; (4) Compound Org214444–0, N-(2-((2-bromo-4-((4R,7S)-3-cyano-2-
methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)-4,5-difluorophenyl)
methanesulfonamide [68]; (5) Compound 10, N-(1-acetyl-2,2,4-trimethyl-4-phenyl-1,2,3,4-tetrahydroquinolin-
6-yl)-[1,1′-biphenyl]-4-carboxamide [67]; (6) Compound 1, 7-{4-[bis-(2-carbamoyl-ethyl)-amino]-6-chloro-
(1,3,5)-triazin-2-ylamino)-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene}-2-sulfonic acid sodium salt [71].
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In 2006, the compound Org214444–0, a derivative of 4-phenyl-5-oxo-
l,4,5,6,7,8-hexahydroquinolines (Figure 4), was developed, which in the absence 
of FSH caused the AC activation in CHO cells expressing the FSH receptor (EC50 
about 1 nM) and stimulated the steroidogenesis in the human and rat granulosa 
cells [68, 69]. Moreover, Org214444-0 increased the FSH affinity to receptor 
and the efficiency of FSH-induced AC stimulation, which makes it possible to 
identify this compound as ago-PAM. Oral administration of Org214444-0 led 
to the stimulation of the folliculogenesis and induced the ovulation in mature 
female rats, indicating the stability and effective absorption of Org214444-0 in the 
gastrointestinal tract [69].
Compound 10, a tetrahydroquinoline derivative (Figure 4), with a high effi-
ciency inhibited FSH-induced follicular growth and ovulation in mice [67]. There 
is reason to believe that compound 10 prevents the functional interaction between 
the extracellular and serpentine domains of FSH receptor and, thereby, disrupts 
the signal transduction from the ligand-binding site located within an ectodomain 
to the intracellular regions of receptor that are involved in the interaction with 
the Gs proteins. This characterizes this compound as NAM for FSH receptor [67]. 
Additionally, it has been shown that the 7-{4-[bis-(2-carbamoyl-ethyl)-amino]-
6-chloro-(1,3,5)-triazin-2-ylamino)-4-hydroxy-3-(4-methoxy-phenylazo)-
naphthalene}-2-sulfonic acid (compound 1) (Figure 4), also belonging to NAM for 
FSH receptor, in a dose-dependent manner reduced the specific FSH binding to the 
receptor, suppressed the stimulating effects of FSH on the AC activity and steroido-
genesis, and in the in vivo conditions prevented FSH-induced ovulation in female 
rats [71, 74].
Among the benzamide derivatives, the most active were the compounds 
ADX61623, ADX68692, and ADX68693, which demonstrated the activity of alloste-
ric antagonists of FSH receptor [75, 76]. These compounds had an unusual phar-
macological profile, which, as may be supposed, was due to the complexity of their 
effect on the FSH-stimulated signaling in the target cells. In the in vitro conditions, 
the N-(4-(2-cyanopropane-2-yl)phenyl)-3,4-dimethoxybenzamide (ADX61623) at 
the low concentrations inhibited FSH-induced production of cAMP and progester-
one in follicular cells, while at the high concentrations, it increased the production 
of estradiol [75]. Of the three benzamide derivatives, only the ADX68692 was active 
when administered orally and subcutaneously to mature female rats, dysregulat-
ing the sexual cycle and reducing the number of matured oocytes [76]. However, 
it should be noted that the ADX68692 was able to modulate the activity of LH 
receptor, enhancing the production of progesterone and reducing the synthesis of 
testosterone in the rat Leydig cells [77].
In conclusion, it should be noted that despite the large number of the investi-
gated allosteric ligands of FSH receptor, they are not yet used in the clinic due to the 
many unresolved problems with their bioavailability, the mechanisms of action, 
and possible undesirable effects [57, 58]. However, the limitations with the use 
of commercial FSH drugs in the clinic and the need to develop the selective FSH 
receptor inhibitors are a good stimulus to further development of the LMW ligands 
of FSH receptor and their implementation into clinical practice.
5. Conclusion and future perspectives
Summing up the current results in the development and study of the LMW allo-
steric ligands of the LH and FSH receptors, it is necessary to focus on the following 
advantages, which are important for their application for reproduction and molecu-
lar and clinical endocrinology, including the assisted reproductive technologies.
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i. The LMW allosteric agonists of the gonadotropins receptors do not 
compete with the gonadotropins for the binding sites and, thus, do not 
suppress the effects of LH, hCG, and FSH, and in some cases they enhance 
them, acting as PAM or ago-PAM. The inhibition of the stimulating effect 
of gonadotropins by the LMW allosteric inverse agonists and NAMs is due 
to their allosteric effects, but not the result of the competition for receptor 
binding sites.
ii. The LMW ligands of the LH and FSH receptors are characterized by the 
selectivity for intracellular signaling cascades, functioning as the bias 
ligands, which allows predicting and determining the functional response of 
cells to their action and prevents a number of undesirable side effects that are 
detected when gonadotropins are used.
iii. Since the LMW agonists are selective, they, unlike gonadotropins, have a 
little effect on the β-arrestin signaling pathways responsible for downregula-
tion of the receptors. As a result, under conditions of treatment with the 
LMW allosteric agonists, the sensitivity of the tissues to endogenous gonado-
tropins is preserved, which makes it possible to use the long-term courses of 
LMW agonists as well as to use them with the gonadotropins.
iv. The LMW allosteric ligands of the LH and FSH receptors can be active 
not only with their parenteral routes of administration but also with their 
oral delivery, since they are stable in the gastrointestinal tract and are well 
absorbed by intestinal cells.
v. The LMW agonists have chaperone-like properties in relation to the LH 
and FSH receptors, preventing their intracellular degradation and increas-
ing their translocation to the plasma membrane. In this regard, the LMW 
agonists can be used to enhance the response of the reproductive system to 
the gonadotropins in the case of the mutant LH and FSH receptors that are 
not capable of translocation as well as in the conditions of the metabolic, 
inflammatory, and autoimmune disorders inducing the impaired posttrans-
lational processing of these receptors. It should be noted that the mutations 
and polymorphisms in the gonadotropin receptors lead to a decrease in the 
sensitivity of the testes and ovaries to gonadotropins [78, 79]. In the assisted 
reproductive technologies, they reduce the response of the ovaries to the 
gonadotropin stimulation, which leads to the impaired folliculogenesis, the 
reduced output of high-quality oocytes, and the deterioration of the devel-
opment and implantation of the embryo [78, 80]. Since both gonadotropins, 
LH and FSH, play an important role in the development and maturation of 
the follicles and oocytes, the polymorphisms in the LH and FSH receptors 
can be the main causes of an impairment of folliculogenesis and oogenesis, 
including their late stages [79, 81, 82].
Despite the advantages listed above, the LMW allosteric ligands of the LH and 
FSH receptors have not yet found use in the clinic. The main reason is insufficient 
knowledge of the pharmacokinetics and the distribution of these compounds in 
the body, as well as the problems with the development of their dosage forms, 
especially since most of these compounds are highly hydrophobic and dissolve in 
DMSO. The attempts to reduce the hydrophobicity of LMW ligands by modify-
ing their structure lead to the partial or complete loss of their specific activity, 
due to their reduced ability of penetration into the transmembrane channel of 
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the gonadotropins receptors. The most promising approach to solve this problem 
is to use the solubilizing agents that can increase the water solubility of these 
compounds.
Thus, the development of the LMW allosteric ligands of the gonadotropin 
receptors, which have a high specificity in regulating certain signaling pathways 
and effector systems in the testicular and ovarian cells, opens up a promising way 
to create a new generation of highly selective drugs that can be used to treat and 
prevent the reproductive disorders and in assisted reproductive technologies, both 
separately and in combination with gonadotropins and other regulators of the 
hypothalamic-pituitary-gonadal axis.
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